{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:54:47Z","timestamp":1782528887841,"version":"3.54.5"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Most tubo-ovarian high-grade serous carcinomas (TO-HGSC) are diagnosed in advanced stages. Although the majority of patients achieve initial remission with cytoreductive surgery and chemotherapy, mortality rate remains high due to recurrent\/progressive disease. The addition of trastuzumab to carboplatin-paclitaxel improved progression-free survival of patients with human epidermal growth factor receptor 2 (HER2)-positive uterine serous carcinoma. After this encouraging result of transtuzumab in HER2-positive uterine serous carcinoma, we aimed to determine the frequency of HER2 overexpression\/amplification in TO-HGSC and reveal the utility of 2018 ASCO\/CAP HER2 testing guideline in breast cancer for TO-HGSC. For 100 cases, HER2 protein expression was assessed by immunohistochemistry and scored from 0 to 3+ according to 2018 ASCO\/CAP HER2 testing guideline. <jats:italic toggle=\"yes\">HER2<\/jats:italic> gene amplification was assessed by florescence <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization for all the 2+ and 3+ cases as well as 5 of the 0\/1+ cases. Among 100 cases, immunohistochemistry scores were 0\/1+ in 81 cases, 2+ in 18 cases and 3+ in 1 case. By florescence <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization, the only 3+ case and 1 of the 2+ cases were HER2-amplified and all 5 of the 0\/1+ cases were HER2 nonamplified. Subclonal HER2 overexpression\/amplification was identified in 1 of the neoadjuvant cases comprising &lt;10% of the entire tumor. In summary, HER2 overexpression\/amplification was found in 2% of TO-HGSC. The 2018 ASCO\/CAP HER2 testing guideline in breast cancer can be utilized for TO-HGSC. Future studies are needed to explore HER2-targeted therapies in TO-HGSC and expand the patient population who may benefit from HER2-targeted therapies such as patients with activating mutations in <jats:italic toggle=\"yes\">HER2<\/jats:italic> gene without overexpression\/amplification.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000812","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T18:00:48Z","timestamp":1627495248000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas"],"prefix":"10.1097","volume":"41","author":[{"given":"Esma","family":"Ersoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing Jackie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N.","family":"Otis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-20250802","first-page":"65","article-title":"Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer","volume":"15","author":"Yano","year":"2006","journal-title":"Oncol Rep"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/modpathol.3800712","article-title":"Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus","volume":"20","author":"Reichelt","year":"2007","journal-title":"Mod Pathol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"e1138","DOI":"10.1371\/journal.pone.0001138","article-title":"HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients","volume":"2","author":"Tuefferd","year":"2007","journal-title":"PLoS One"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20250802","first-page":"40","article-title":"HER2-positive metastatic breast cancer: a comprehensive review","volume":"19","author":"Exman","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40265-021-01485-2","article-title":"Margetuximab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R14-20250802","first-page":"635","article-title":"Expression of HER2\/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary","volume":"14","author":"Karaferic","year":"2009","journal-title":"J BUON"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2559.2005.02306.x","article-title":"HER-2\/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays","volume":"48","author":"Mayr","year":"2006","journal-title":"Histopathology"},{"key":"R16-20250802","first-page":"154","article-title":"HER2\/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance","volume":"68","author":"Verri","year":"2005","journal-title":"Clin Study Oncol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn Pathol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1157\/13096935","article-title":"Overexpression and prognostic value of p53 and HER2\/neu proteins in benign ovarian tissue and in ovarian cancer","volume":"128","author":"Coronado Mart\u00edn","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/PGP.0000000000000302","article-title":"Pattern of HER-2 gene amplification and protein expression in benign, borderline, and malignant ovarian serous and mucinous neoplasms","volume":"36","author":"Mohammed","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20250802","first-page":"4222","article-title":"HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis","volume":"7","author":"Kim","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/jclinpath-2011-200616","article-title":"HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis","volume":"65","author":"McCaughan","year":"2012","journal-title":"J Clin Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2003.10.010","article-title":"ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma","volume":"92","author":"Lassus","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-019-02528-6","article-title":"Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK\/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma","volume":"474","author":"Schmoeckel","year":"2019","journal-title":"Virchows Arch"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8","article-title":"Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy","volume":"75","author":"Felip","year":"1995","journal-title":"Cancer"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004347-199401000-00006","article-title":"Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression","volume":"13","author":"Meden","year":"1994","journal-title":"Int J Gynecol Pathol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cncr.11476","article-title":"Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study","volume":"98","author":"H\u00f8gdall","year":"2003","journal-title":"Cancer"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/annonc\/mdh021","article-title":"HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group","volume":"15","author":"Camilleri-Bro\u00ebt","year":"2004","journal-title":"Ann Oncol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ijgc-00009577-200707000-00008","article-title":"The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer","volume":"17","author":"Steffensen","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/IGC.0b013e3181991a7c","article-title":"Prognostic value of human epidermal growth factor receptor 2 (Her-2)\/neu in patients with advanced ovarian cancer treated with platinum\/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany","volume":"19","author":"Pfisterer","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4149\/neo_2016_520","article-title":"The impact of p16 and HER2 expression on survival in patients with ovarian carcinoma","volume":"63","author":"Shandiz","year":"2016","journal-title":"Neoplasma"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.1998.5094","article-title":"Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure","volume":"70","author":"Goff","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.gore.2019.07.001","article-title":"Afatinib use in recurrent epithelial ovarian carcinoma","volume":"29","author":"Shepherd-Littlejohn","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jmoldx.2015.04.003","article-title":"Mutations in the kinase domain of the HER2\/ERBB2 gene identified in a wide variety of human cancers","volume":"17","author":"Wen","year":"2015","journal-title":"J Mol Diagn"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:54Z","timestamp":1754161434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000812","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,28]]}}}